SLOREL
Live / Registered — Registered (as of 08 Jul 2025)
What this means for you
Registered since 08 Jul 2025. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97593502
- Registration number
- 7854495
- Mark type
- Stylized text
- Filed
- 15 Sept 2022
- Published for opposition
- 20 May 2025
- Registered
- 08 Jul 2025
- Attorney of record
- Caroline E. Bryce
Goods and services
- Class 005 — Pharmaceuticals: Surgical implants comprised of living tissues for guided tissue regeneration; implants comprising living tissue; implantable materials for use in guided tissue regeneration in the nature of implants comprising living tissue; Surgical implants comprised of living tissues used in transplants, namely, vascular grafts being living tissue and human allograft tissue; surgical implants comprised of living tissues; human allograft tissue; bone void fillers comprised of living tissues; Stem cells for medical purposes, namely, surgical implants grown from stem cells; pharmaceutical preparations for use in tissue transplantation; pharmaceutical preparations for tissue regeneration; medicines for human purposes, namely, pharmaceutical preparations for the treatment of musculo-skeletal disorders; medicines for human purposes, namely, a drug delivery system comprising liquids, powders, tablets or capsules for the continuous release of a wide variety of therapeutic agents, namely, pharmaceutical preparations for the treatment of musculo-skeletal disorders; drugs for medical purposes, namely, drugs for use in bioregenerative procedures, drugs for use for regenerative purpose, drugs for use to assist with artificial bone growth, drugs for use in accelerating bone formation, drugs for use to stimulate new bone formation; pharmaceutical agents affecting sensory organs; pharmaceutical preparations for the prevention of diseases of the musculo- skeletal system; pharmaceutical preparations for the treatment of Musculo-skeletal disorders; cellular function activating agents for medical purposes; pharmaceutical preparations for use in organ transplantation; biological tissue cultures for medical purposes; drug delivery agents in the form of liquid, powders, tablets and capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of dissolvable films added to bone substitutes that facilitate the delivery of pharmaceutical preparations; drug delivery agents in the form of dissolvable films for use in bioregenerative procedures that facilitate the delivery of pharmaceutical preparations; drug delivery agents in the form of dissolvable films that provide sustained release of drugs for use with implants and bone substitutes that facilitate the delivery of pharmaceutical preparations; drug delivery agents in the form of drug delivery compounds that facilitate sustained or extended release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of dissolvable films with controlled timing and rate of drug release that facilitate the delivery of pharmaceutical preparations; medicines for human use, namely pharmaceutical preparations for the treatment of musculo-skeletal disorders featuring controlled timing and rate of release; medical bone graft substitute, namely, biological tissue bone grafts; medical bone graft materials, namely, bone fillers consisting of living materials; medical bone graft materials with drug release function being bone growth media consisting of biological materials for medical bone graft purposes with drug release function; medical bone graft materials, namely, biological bone tissue intended for subsequent implantation in a bone graft with drug release function, that provide sustained release of drugs for use with implants and bone substitutes; medical bone graft materials being biological bone tissue intended for subsequent implantation with drug release function that are sold filled with pharmaceutical preparations, namely, biological growth factors, used with implants and bone substitutes; medical bone graft materials being biological bone tissue intended for subsequent implantation with drug release function that are sold filled with pharmaceutical preparations, namely, antibiotics, used with implants and bone substitutes
Owner
- CG Bio Co., Ltd., Gyeonggi-do, KR
- CG Bio Co., Ltd., Gyeonggi-do, KR
- CG Bio Co., Ltd., Gyeonggi-do, KR
Prosecution history
- 08 Jul 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 08 Jul 2025 — REGISTERED-PRINCIPAL REGISTER
- 20 May 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 20 May 2025 — PUBLISHED FOR OPPOSITION
- 14 May 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 17 Apr 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 14 Mar 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 14 Mar 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 14 Mar 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 08 Jan 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 08 Jan 2025 — NON-FINAL ACTION E-MAILED
- 08 Jan 2025 — NON-FINAL ACTION WRITTEN
- 17 Dec 2024 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 12 Dec 2024 — TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
- 12 Dec 2024 — TEAS CHANGE OF CORRESPONDENCE RECEIVED